Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	118.37	234.7	119.22	148.2	120.68
Short-Term Investments	217.63	128.6	622.2	220.31	301.08
Cash & Cash Equivalents	336	363.29	741.42	368.51	421.76
Cash Growth	-7.51%	-51.00%	101.19%	-12.63%	18.80%
Receivables	234.21	231.07	90.98	97.73	59.44
Inventory	127.6	100.12	53.91	60.75	29.36
Other Current Assets	48.61	44.52	39.98	27.77	32.87
Total Current Assets	746.42	739.01	926.29	554.76	543.44
Property, Plant & Equipment	74.94	75.57	8.79	10.59	10.86
Goodwill and Intangibles	889.7	955.7	0	0	0
Other Long-Term Assets	22.2	71.23	169.35	14.57	11.58
Total Long-Term Assets	986.85	1,102	178.14	25.16	22.44
Total Assets	1,733	1,842	1,104	579.92	565.87
Accounts Payable	11.82	17.69	1.54	1.93	6.43
Deferred Revenue	0	0	4.28	5.77	5.26
Current Debt	0	13.33	89.42	397.23	19.54
Other Current Liabilities	100.68	99.76	21.91	16.46	54.4
Total Current Liabilities	112.49	130.79	117.15	421.39	85.64
Long-Term Debt	1,499	1,493	787.26	0	383.05
Other Long-Term Liabilities	37.72	48.16	3.07	7.49	5.43
Total Long-Term Liabilities	1,537	1,541	790.33	7.49	388.47
Total Liabilities	1,649	1,672	907.48	428.88	474.11
Total Debt	1,499	1,506	876.67	397.23	402.59
Debt Growth	-0.45%	71.80%	120.70%	-1.33%	218.55%
Retained Earnings	90.55	143.22	-58.91	-474.59	-603.68
Comprehensive Income	-9.28	-0.92	-0.62	0.02	0.24
Shareholders' Equity	83.81	169.8	196.95	151.05	91.77
Net Cash / Debt	-1,163.25	-1,142.81	-135.25	-28.72	19.18
Net Cash / Debt Growth	-	-	-	-	-91.61%
Net Cash Per Share	-8.67	-8.13	-0.92	-0.20	0.13
Working Capital	633.93	608.22	809.14	133.38	457.8
Book Value Per Share	0.64	1.24	1.40	1.11	0.64

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).